F-c Bidard

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open

Published: January 05, 2026

Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

Journal: ESMO open

Published: December 10, 2025

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Journal: ESMO open

Published: November 11, 2025

Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer.

Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer.

Journal: ESMO open

Published: October 28, 2025

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2025

Blood tumor load: combining biomarkers to increase the proportion of informative patients.

Blood tumor load: combining biomarkers to increase the proportion of informative patients.

Journal: ESMO open

Published: August 13, 2024

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

Journal: ESMO open

Published: June 28, 2024

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Journal: British journal of cancer

Published: March 31, 2024

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 21, 2023

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 18, 2022

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 08, 2022

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 21, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026